Clinical Trial Update: ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer. [Phase 2]

View source ↗

Summary

Phase II study of alternating eribulin and hormonal therapy in pre-treated ER-positive breast cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)
• Hormonal Therapy

Snippet

Sponsor: Imperial College London | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-02-05